Sympathomimetics are a class of drugs that mimic the effects of the sympathetic nervous system, often called the fight-or-flight system. When these drugs bind to adrenergic receptors, they trigger physiological responses designed to help the body handle stress. In the respiratory system, this activation leads to the relaxation of bronchial smooth muscle, opening up narrowed airways and making it easier to breathe. Understanding this foundation helps nurses anticipate how patients will react to bronchodilator therapy during an acute respiratory crisis.
At the cellular level, respiratory sympathomimetics target specific adrenergic receptors located on airway smooth muscle cells.
This cascade explains why these agents reverse acute bronchoconstriction rapidly.
Respiratory sympathomimetics are categorized based on their duration of action and receptor specificity. Clinicians use these categories to tailor treatment plans for either immediate rescue or long-term disease control.
| Classification | Onset of Action | Duration of Action | Primary Clinical Use |
|---|---|---|---|
| Short-Acting Beta-Agonists (SABAs) | Rapid (minutes) | 3 to 6 hours | Acute bronchospasm relief |
| Long-Acting Beta-Agonists (LABAs) | Slower | 12 hours or more | Maintenance and nocturnal control |
Selecting the correct category prevents inappropriate drug use, such as relying on a maintenance medication during an acute asthma attack.
Short-acting beta-agonists like salbutamol are the frontline defense during acute bronchospasm episodes, such as asthma attacks or severe chronic obstructive pulmonary disease exacerbations. They act within minutes to restore airflow, relieving distressing symptoms like wheezing and shortness of breath. Nurses must monitor clients closely after administration, as frequent reliance on a rescue inhaler often signals worsening, poorly controlled underlying inflammation that requires escalation of anti-inflammatory therapy.
Long-acting agents like formoterol and salmeterol provide sustained bronchodilation lasting twelve hours or longer. They are prescribed for daily maintenance therapy to prevent bronchospasm, particularly nocturnal symptoms in asthma or chronic bronchitis. LABAs must never be used as monotherapy in asthma management due to safety warnings regarding severe exacerbations; instead, they are combined with inhaled corticosteroids to target both bronchoconstriction and airway inflammation safely.
Before administering any sympathomimetic, the nurse must perform a targeted respiratory assessment, noting baseline respiratory rate, breath sounds, oxygen saturation, and work of breathing. Post-administration checks are equally vital to evaluate therapeutic efficacy and detect early signs of systemic absorption. Nurses should also review the client's cardiac history, as adrenergic stimulation naturally increases heart rate and can precipitate arrhythmias or myocardial ischemia in vulnerable individuals.
Although inhaled delivery targets the lungs, systemic absorption of sympathomimetics is common and produces predictable side effects. Clients frequently report fine skeletal muscle tremors, nervousness, restlessness, and palpitations. At high doses or during toxicity, these agents can cause severe tachycardia, hypokalemia, and dangerous cardiac arrhythmias. Recognizing these adverse reactions allows nurses to reassure clients experiencing mild jitteriness while intervening promptly if true toxicity develops.
Proper inhaler technique dictates whether medication reaches the distal airways or merely coats the oral cavity. Nurses must teach clients how to use Metered-Dose Inhalers (MDIs) correctly, recommending spacer devices to minimize local side effects like hoarseness and oral candidiasis. Clients should demonstrate the technique back to the nurse, ensuring they exhale fully, actuate the device while inhaling slowly, and hold their breath for ten seconds to maximize drug deposition.